In this carefully conducted systematic review, the authors found that correctional facilities should scale up opioid agonist treatment (methadone and buprenorphine) among incarcerated persons with opioid use disorder. The strategy is likely to decrease opioid-related overdose and mortality, reduce opioid use and other risky behaviors during and after incarceration, and improve retention in addiction treatment after prison release.
Source: PLOS Medicine
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003002
